headerhome

Opening New Frontiers By Advancing The Promise of PI Signaling Pathways

Charles L. Sawyers, M.D.

Select a team to find out more

Charles L. Sawyers, M.D.

Charles L. Sawyers, M.D.

Investigator, Howard Hughes Medical Institute, Marie-Josée and Henry Kravis Chair in Human Oncology and Pathogenesis, Chairman, Human Oncology & Pathogenesis Program, Memorial Sloan Kettering Cancer Center

Dr. Charles Sawyers received a B.A. from Princeton University in 1981 and earned a M.D. in 1985 from Johns Hopkins University School of Medicine, followed by internal medicine residency at UCSF.  He became an investigator for the Howard Hughes Medical Institute in 2002 while at UCLA, and then moved to Memorial Sloan Kettering Cancer Center in 2006 where he currently serves as the Chair of the Human Oncology and Pathogenesis Program.

Sawyers studies mechanisms of cancer drug resistance with an eye toward developing novel therapies.  He co-discovered the antiandrogen drug enzalutamide that was approved by the FDA in 2012 for treatment of advanced prostate cancer.  He shared the 2009 Lasker~DeBakey Clinical Medical Research Award for the development of the ABL kinase inhibitor imatinib for patients with chronic myeloid leukemia and the second-generation ABL inhibitor dasatinib to overcome imatinib resistance.  Other accolades include: the 2013 Breakthrough Prize in Life Sciences; the 2013 Taubman Prize for Excellence in Translational Medical Science; and the 2015 BBVA Knowledge Award in Biomedicine.

Sawyers is a member of the National Academy of Sciences, the Institute of Medicine and the American Academy of Arts and Sciences.  He is past President of the American Association for Cancer Research (AACR) and the American Society of Clinical Investigation (ASCI).  He was appointed to the National Cancer Advisory Board by President Obama and has served since 2013 on the board of Novartis.

timelinearrowleft

timelinearrowright